Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study Full Text
World Journal of Gastroenterology,  Clinical Article

Tack GJ et al. – The study aims to assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN–PEP) to mitigate the immunogenic effects of gluten in celiac patients. AN–PEP appears to be well tolerated. However, the primary endpoint was not met due to lack of clinical deterioration upon placebo, impeding an effect of AN–PEP.

Methods

  • Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included.
  • In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase).
  • After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase).
  • Measurements at baseline included complaints, quality-of-life, serum antibodies, immunophenotyping of T-cells and duodenal mucosa immunohistology.
  • Furthermore, serum and quality of life questionnaires were collected during and after the safety, washout and efficacy phase.
  • Duodenal biopsies were collected after the safety phase and after the efficacy phase.
  • A change in histological evaluation according to the modified Marsh classification was the primary endpoint.

Results

  • In total, 16 adults were enrolled in the study.
  • No serious adverse events occurred during the trial and no patients withdrew during the trial.
  • The mean score for the gastrointestinal subcategory of the celiac disease quality (CDQ) was relatively high throughout the study, indicating that AN-PEP was well tolerated.
  • In the efficacy phase, the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed.
  • During the efficacy phase, neither the placebo nor the AN-PEP group developed significant antibody titers.
  • The IgA-EM concentrations remained negative in both groups.
  • Two patients were excluded from entering the efficacy phase as their mucosa showed an increase of two Marsh steps after the safety phase, yet with undetectable serum antibodies, while 14 patients were considered histologically stable on gluten with AN-PEP.
  • Also after the efficacy phase, no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP.
  • Furthermore, IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo.
  • In the seven patients receiving AN-PEP, one patient showed increased and one showed decreased IgA-tTG deposits.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Gastroenterology Articles

1 Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial Neurogastroenterology & Motility, February 10, 2014    Clinical Article

2 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , June 25, 2014    Evidence Based Medicine    Clinical Article

3 The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients Journal of Crohn's and Colitis, June 11, 2014    Clinical Article

4 Effect of a low-flatulogenic diet in patients with flatulence and functional digestive symptoms Neurogastroenterology & Motility, February 25, 2014    Clinical Article
Exclusive Author Commentary

5 First-line treatment strategies for Helicobacter pylori infection Full Text Gastroenterology & Endoscopy News, March 12, 2014    Free full text

6 Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: Systematic review and meta-analysis The American Journal of Gastroenterology, June 18, 2014    Review Article

7 Safety of gastrointestinal endoscopic biopsy in patients taking antithrombotics Digestive Endoscopy, May 5, 2014    Clinical Article

8 Magnetic resonance enterography vs. computed tomography enterography for evaluating disease activity in small bowel Crohn's disease Alimentary Pharmacology and Therapeutics, June 12, 2014    Evidence Based Medicine    Review Article

9 Mortality after total colectomy in 3084 patients with inflammatory bowel disease: a population-based cohort study Alimentary Pharmacology and Therapeutics, June 23, 2014    Clinical Article

10 Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis Clinical Gastroenterology and Hepatology , June 26, 2014    Clinical Article

11 Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta-analysis Clinical Gastroenterology and Hepatology , June 2, 2014    Evidence Based Medicine

12 Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: A randomized, double-blind, placebo-controlled study Journal of Crohn's and Colitis, June 27, 2014    Clinical Article

13 Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease Full Text BMC Gastroenterology, May 12, 2014    Free full text    Clinical Article

14 Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease Gastroenterology, April 2, 2014    Clinical Article

15 Therapy of inflammatory bowel disease: what to expect in the next decade Current Opinion in Gastroenterology, June 13, 2014    Review Article

16 Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: A meta-analysis PLOS ONE, December 11, 2013    Evidence Based Medicine    Clinical Article

17 Risk and management of intra-abdominal abscess in Crohn's disease treated with infliximab Digestion, May 2, 2014    Clinical Article

18 Steroids versus dietary therapy for the treatment of eosinophilic esophagitis Current Opinion in Gastroenterology, June 11, 2014    Clinical Article

19 Helicobacter pylori infection increases subsequent ischemic stroke risk: a nationwide population-based retrospective cohort study QJM: An International Journal of Medicine, June 20, 2014    Clinical Article

20 Risks of serious infection or lymphoma with anti–tumor necrosis factor therapy for pediatric inflammatory bowel disease: A systematic review Clinical Gastroenterology and Hepatology , May 28, 2014    Review Article    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close